在HFpEF的ZSF1老鼠模型中,PDE9A抑制改善了冠状动脉微血管稀疏和左心室扩张功能障碍

相关实验视频

Updated: Jun 12, 2025

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

Katie Anne Fopiano¹, Saltanat Zhazykbayeva^2,3,4, Ibrahim El-Battrawy^2,3,4

¹Department of Physiology, Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

Microcirculation (New York, N.Y. : 1994)

|September 26, 2024

概括

在心力衰竭模型中,选择性固酶9A (PDE9A) 抑制改善了冠状动脉微血管疾病和心脏静脉功能障碍. 这种方法可以通过增强抗氧化机制,为心脏代谢疾病提供新的治疗方法.

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.
生物化学生物化学

背景情况:

保持喷射分数 (HFpEF) 的心力衰竭通常与高血压,肥胖和糖尿病等疾病有关.
冠状动脉微血管疾病 (CMD) 是在HFpEF中发展左心室 (LV) 扩张功能障碍的一个重要因素.
选择性固酶9A (PDE9A) 抑制是心脏代谢疾病的潜在治疗策略.

研究的目的:

调查PDE9A抑制如何可以缓解CMD,并改善HFpEF中的LV扩张功能.
在相关的HFpEF模型中探索PDE9A抑制的潜在机制.

主要方法:

使用肥胖糖尿病的Zucker脂肪/自发高血压心力衰竭F1混合 (ZSF1) 鼠标模型的HFpEF.
给ZSF1大鼠服用选择性PDE9A抑制剂 (PF04447943) 并评估冠状动脉微血管稀缺和LV透缩功能.
分析了氧化和化应激标志物,并采用蛋白质组分析来识别抗氧化剂变化.

主要成果:

肥胖的ZSF1大鼠表现出冠状动脉微血管稀缺和LV透静功能障碍,心脏PDE9A表达增加.
在ZSF1大鼠中,PF04447943治疗改善了冠状动脉微血管稀缺症和LV静脉静脉动态功能障碍.
治疗降低了氧化和化应激标志物,并提高了氧化素5 (PRDX5) 蛋白水平.

结论:

在HFpEF的ZSF1大鼠模型中,抑制PDE9A可以改善CMD和LV的透析功能障碍.
治疗效益与增强的百氧化依赖性抗氧化机制有关.
PDE9A抑制剂在治疗与心脏代谢疾病相关的HFpEF方面表现有前途.

关键词:

腹痛功能障碍腹痛功能障碍腹痛功能障碍微血管稀缺症是一种微血管稀缺症.氧化应激是一种氧化应激.

更多相关视频

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

相关概念视频

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...